A randomized, placebo-controlled, double-blind study to evaluate safety and dose dependent clinical efficacy of APO-2 at three different doses in patients with diabetic foot ulcer

+43 664 212 05 57

What is the clinical study about – what is being investigated?

This clinical trial is a scientific study of patients with diabetic foot ulcers. The study drug used in this clinical trial is called APO-2 and is in clinical development as a drug for external use and has not yet been approved.
APO-2 is being investigated for the treatment of wound healing disorders in skin wounds. The aim of the study is to prove that a new drug (gel) is well tolerated for the treatment of poorly healing, diabetic foot wounds. One possible benefit of the new drug is faster and more permanent wound closure.
Since this is a placebo-controlled study, it is possible that instead of the drug, you will also receive a gel without novel active ingredients. In any case, however, you will receive intensive treatment of your wound by experienced doctors.

Recruitment has been stopped
because the required number of patients had already been treated!

You can find further information at: